Dan Li joined Delos Capital as a Principal in April 2021, prior to which he was an Executive Vice President of Sinopharm Capital and Investment Director of Shiyu Capital, focusing on investing in early-stage biotech companies in Greater China.

Dan has over 10 years of experience in the pharmaceutical industry, with a broad range of roles (including marketing, strategy and BD) covering various therapeutical disease areas at Roche and Sanofi based in Shanghai. Dan graduated from Fudan University and University of Cincinnati, and holds dual Master’s degree in Physics and Biomedical Engineering.